Since the onset of the COVID-19 pandemic, scientists had predicted (and feared) its possible intersection with fungal infections.

In the last twenty years, three coronaviruses have managed to make the leap in human species and spread globally: SARS-Cov in 2003, MERS-Cov in 2012 and SARS-Cov-2 in 2019.

Messenger RNA vaccines (mRNA vaccines) were the big players in the arms race against the SARS-CoV-2 virus and the first to be commercialized.

The clinical trial for the second Italian vaccine, developed by the Roman company Takis in collaboration with Rottapharm biotech, has started last week. The first volunteer vaccinated with COVID-eVax  is Luca Rivolti, a 21 year old man from Monza. COVID-eVax, is a DNA-based vaccine, different from all the others already authorized.

From model organisms for oncology research to “avatars” for personalized medicine: fruit flies can develop tumors very similar to humans and contribute to the search for new therapies to increase patient survival.

One year after the onset of the Covid-19 pandemic, the first doses of the vaccine were administered. For other infectious diseases, however, dozens of years of research were not enough to create a completely effective vaccine.

A preventive vaccine could be the new hope against triple negative breast cancer, which does not respond to any drug therapy.

It belongs to the same family as Sars-Cov-2, but affects a different species. The feline enteric coronavirus (FEPV) is a harmless gastrointestinal virus that can mutate into an aggressive form responsible for a lethal systemic disease - feline infectious peritonitis (FIP).